

Dear Editors and Reviewers:

Thank you very much for reviewing our manuscript entitled, “Therapeutic Advances in Non-alcoholic Fatty Liver Disease with a Microbiota-centered View” [Manuscript NO: 53881]. We also sincerely thank the reviewers for their constructive comments and suggestions. Due to the recent pneumonia epidemic in China, our team is busy with clinical work, so the time required for the revision of this manuscript took more. Please accept our most sincere apologies, and thanks again for the editors and reviewers’ patience and understanding! Accordingly, we have carefully revised the manuscript. All amendments are highlighted in the revised manuscript. In addition, point-by-point responses to the comments are on the subsequent pages.

We hope that the revisions are acceptable for publication in your journal.

We look forward to hearing from you soon.

Yours sincerely,

Yongjian Zou

Point-to point responses

First of all, we would like to express our sincere gratitude to the reviewers for their constructive comments and suggestions.

Replies to Reviewer 1

1. Please stated better the aim of your study in the abstract and in the introduction section.

Response: Thank you very much for your constructive comments. Accordingly, we have included some statements regarding this issue in the revised manuscript.

2. Please specify the kind of review made (narrative, systematic, meta analyses and so on).

Response: Thank you very much for your constructive comments. Accordingly, we have included statement in INTRODUCTION.

3. The first paragraph of the introduction section is without adequate reference, please provide to quote adequate reference

Response: Thank you very much for your valuable comments and suggestions. We have already quoted adequate references accordingly. It's really kind for you to provide us with such valuable studies to improve our review.

4. Please improve the introduction section, it is too poor. Please add a sentence regarding Fatty liver disease, nutrition and lifestyle.

Response: Many thanks again for your valuable comments and suggestions. We have already included some statements regarding this issue in the revised manuscript and quoted adequate references accordingly.

Replies to Reviewer 2

1. Minor language polishing

Response: This revised manuscript has been edited and proofread by *CureEdit* Co.. Thank you very much for this critical comment.

2. Description of the association between the pathogenesis of NAFLD and gut microbiota is lacking. I recommend to the authors to briefly summarize the mechanism of gut microbiota (in immune point and metabolite point) on the pathogenesis of NAFLD between the “introduction” and “antibiotics” section.

Response: Thank you very much for your constructive comments. This is indeed a deficiency in our manuscript. Accordingly, we have included some statements regarding this issue in the revised manuscript.

3. More than 130 clinical studies are currently ongoing targeting NAFLD. Among these, I would like to recommend the authors to organize the clinical research (centered on phase 2 or phase 3) that targets the gut microbiota into a new table other than FMT.

Response: Thank you very much for your constructive comments. Accordingly, we have provided a new table regarding this issue in the revised manuscript. But some researches' PHASE is not available and we excluded.